Q4 2025 Aurobindo Pharma Ltd Earnings Call Transcript
Key Points
- Aurobindo Pharma Ltd (BOM:524804) reported strong financial performance for FY25, with revenues reaching INR31,724 crores and an EBITDA margin of 20.8%.
- The company achieved a significant revenue growth of 11% year-on-year in Q4 FY25, driven by volume gains, new product launches, and stable pricing in regulated markets.
- The European formulation business showed impressive growth, with revenues increasing by 17% year-on-year, nearing the $1 billion mark.
- The specialty and injectable business saw a 25% year-on-year revenue increase in Q4 FY25, indicating strong demand and market presence.
- Aurobindo Pharma Ltd (BOM:524804) improved its cash flow significantly, achieving a net cash surplus of INR42 million by the end of FY25, compared to a net debt position at the end of the previous year.
- The company faced one-time recurring expenses related to fuel and power adjustments, inventory-related provisions, and corporate development costs, impacting the EBITDA by over INR105 crore.
- The growth market revenue declined by 8% year-on-year in Q4 FY25, indicating challenges in key markets.
- The China plant incurred losses of around INR35 crore in its first year, impacting overall profitability.
- The US business faced supply-related disruptions and remediation issues, affecting performance in FY25.
- The Penicillin G facility experienced a fire incident, temporarily halting operations and impacting production timelines.
Ladies and gentlemen, welcome to Aurobindo Pharma's earnings conference call for the fourth quarter of FY25. (Operator Instructions) Please note, this conference is being recorded.
I now hand over the confidence to management for opening remarks. Thank you.
Good morning, and warm welcome to our fourth quarter FY25 earnings call. I'm Shriniwas Dange from the Investor Relations team.
We hope I would now like to introduce my senior management team on the call with us today represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccines, and Peptide businesses and Director Aurobindo Pharma Limited; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialties Limited; Mr. Swami Iyer, CEO, Aurobindo Pharma USA; Mr. Venugopalan Muralidharan, CEO, Europe Formulations business; and then Mr. S. Subramanian, CFO.
We will begin the call with a summary highlights from the management followed by an interactive Q&A session.
Please note that some of the matters we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
